Effects of a dairy product (pecorino cheese) naturally rich in cis-9, trans-11 conjugated linoleic acid on lipid, inflammatory and haemorheological variables: a dietary intervention study

Nutr Metab Cardiovasc Dis. 2010 Feb;20(2):117-24. doi: 10.1016/j.numecd.2009.03.004. Epub 2009 May 27.

Abstract

Background and aim: Some studies recently reported a favourable effect for cis-9, trans-11 conjugated linoleic acid (CLA) on plasma lipoprotein profile of healthy subjects. Aim of this crossover intervention study was to evaluate the influence of a short-term dietary intake of a cheese derived from sheep's milk naturally rich in CLA on several atherosclerotic biomarkers, in comparison with a commercially available cheese.

Methods and results: Ten subjects (6 F; 4 M) with a median age of 51.5 followed for 10 weeks a diet containing 200 g/week of cheese naturally rich in CLA (intervention period) and for the same period a diet containing a commercially available cheese of the same quantity (placebo period). Consumption of the dairy product naturally rich in cis-9, trans-11 CLA determined a significant (p<0.05) reduction in inflammatory parameters such as interleukin-6 (pre: 8.08+/-1.57 vs. post: 4.58+/-0.94 pg/mL), interleukin-8 (pre: 45.02+/-5.82 vs. post: 28.59+/-2.64 pg/mL), and tumour necrosis factor-alpha (pre: 53.58+/-25.67 vs. post: 32.09+/-17.42 pg/mL) whereas no significant differences in the placebo period were observed. With regard to haemorheological parameters, the test period significantly ameliorated erythrocytes' filtration rate (pre: 7.61+/-0.71% vs. post: 9.12+/-0.97%; p=0.03) with respect to the placebo period. Moreover, a reduction in the extent of platelet aggregation, induced by arachidonic acid [pre: 87.8+/-1.76% vs. post: 77.7+/-3.56%; p=0.04] was observed during the test period in comparison with the placebo period.

Conclusions: Dietary short-term intake of the tested dairy product naturally rich in cis-9, trans-11 CLA appeared to cause favourable biochemical changes of atherosclerotic markers.

Publication types

  • Comparative Study
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Viscosity / drug effects
  • Cheese*
  • Cholesterol / blood
  • Cholesterol, LDL / blood
  • Cross-Over Studies
  • Erythrocyte Deformability / drug effects
  • Female
  • Hemorheology / drug effects*
  • Humans
  • Inflammation Mediators / blood*
  • Interleukins / blood
  • Linoleic Acids, Conjugated / administration & dosage*
  • Lipids / blood*
  • Male
  • Middle Aged
  • Milk
  • Platelet Aggregation / drug effects
  • Sheep
  • Time Factors
  • Triglycerides / blood
  • Tumor Necrosis Factor-alpha / blood
  • Vascular Endothelial Growth Factor A / blood

Substances

  • Cholesterol, LDL
  • Inflammation Mediators
  • Interleukins
  • Linoleic Acids, Conjugated
  • Lipids
  • Triglycerides
  • Tumor Necrosis Factor-alpha
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • cis-9, trans-11-conjugated linoleic acid
  • Cholesterol